Laurent Edna Salphati from 514 Diamond St, San Francisco, CA 94114, age 56, Phone: (415)2521084

Resumes

Principal Scientist

view source

Location:

San Francisco, CA

Industry:

Pharmaceuticals

Work:

Genentech
Principal Scientist

Skills:

Pharmacokinetics
Drug Discovery
Drug Metabolism
Drug Development
In Vitro
Assay Development
Clinical Development
Biopharmaceuticals
Pharmacodynamics
Pharmacology
Lc Ms

Us Patents

Tricyclic Pi3K Inhibitor Compounds And Methods Of Use
view source
US Patent:

20120171199, Jul 5, 2012
Filed:

Dec 15, 2011
Appl. No.:

13/326524
Inventors:

Jennafer Dotson - Belmont CA, US
Robert Andrew Heald - , US
Timothy Heffron - Burlingame CA, US
Graham Elgin Jones - , US
Sussie Lerche Krintel - , US
Neville James McLean - , US
Chudi Ndubaku - San Francisco CA, US
Alan G. Olivero - Half Moon Bay CA, US
Laurent Salphati - San Francisco CA, US
Lan Wang - Foster City CA, US
BinQing Wei - Belmont CA, US
International Classification:

A61K 31/5383
C07D 491/147
C07D 498/14
C07D 487/14
C07D 498/22
A61K 31/5386
A61K 31/5377
A61P 35/00
A61P 29/00
A61P 37/02
A61P 25/00
A61P 9/00
A61P 1/16
A61P 31/12
A61P 7/00
A61P 3/10
A61P 37/04
A61P 35/02
C07D 471/14
C07D 495/14
A61K 39/395
US Classification:

4241331, 544115, 544 73, 544 71, 544 74, 5142302, 5142332, 5142328
Abstract:

Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions.Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.

Tricyclic Pi3K Inhibitor Compounds And Methods Of Use
view source
US Patent:

20220348593, Nov 3, 2022
Filed:

Nov 24, 2021
Appl. No.:

17/535124
Inventors:

- South San Francisco CA, US
Robert Andrew Heald - Harlow, GB
Timothy Heffron - Burlingame CA, US
Graham Elgin Jones - Harlow, GB
Sussie Lerche Krintel - Harlow, GB
Neville James McLean - Harlow, GB
Chudi Ndubaku - San Francisco CA, US
Alan G. Olivero - Half Moon Bay CA, US
Laurent Salphati - San Francisco CA, US
Lan Wang - Foster City CA, US
BinQing Wei - Belmont CA, US
International Classification:

C07D 498/22
C07D 471/14
C07D 491/14
C07D 495/14
C07D 487/14
C07D 498/14
A61K 31/5377
A61K 31/5383
A61K 31/5386
A61K 39/395
C07D 491/147
C07D 498/20
C07K 16/22
Abstract:

Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions.Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.

Tricyclic P13K Inhibitor Compounds And Methods Of Use
view source
US Patent:

20190330235, Oct 31, 2019
Filed:

Jul 10, 2019
Appl. No.:

16/507523
Inventors:

- South San Francisco CA, US
Robert Andrew Heald - Harlow, GB
Timothy Heffron - Burlingame CA, US
Graham Elgin Jones - Harlow, GB
Sussie Lerche Krintel - Harlow, GB
Neville James McLean - Harlow, GB
Chudi Ndubaku - San Francisco CA, US
Alan G. Olivero - Half Moon Bay CA, US
Laurent Salphati - San Francisco CA, US
Lan Wang - Foster City CA, US
BinQing Wei - Belmont CA, US
International Classification:

C07D 498/22
C07D 498/20
A61K 31/5377
C07D 471/14
C07D 498/14
A61K 31/5383
A61K 31/5386
A61K 39/395
C07D 491/147
C07D 495/14
C07D 491/14
C07D 487/14
C07K 16/22
Abstract:

Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions.Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.

Tricyclic P13K Inhibitor Compounds And Methods Of Use
view source
US Patent:

20170233407, Aug 17, 2017
Filed:

Dec 9, 2016
Appl. No.:

15/374867
Inventors:

- South San Francisco CA, US
Robert Andrew Heald - Harlow, GB
Timothy Heffron - Burlingame CA, US
Graham Elgin Jones - Harlow, GB
Sussie Lerche Krintel - Harlow, GB
Neville James McLean - Harlow, GB
Chudi Ndubaku - San Francisco CA, US
Alan G. Olivero - Half Moon Bay CA, US
Laurent Salphati - San Francisco CA, US
Lan Wang - Foster City CA, US
BinQing Wei - Belmont CA, US
International Classification:

C07D 498/22
A61K 31/5377
C07K 16/22
A61K 39/395
C07D 495/14
A61K 31/5383
C07D 471/14
C07D 487/14
A61K 31/5386
C07D 491/147
C07D 498/14
Abstract:

Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions.Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.

Tricyclic P13K Inhibitor Compounds And Methods Of Use
view source
US Patent:

20150079081, Mar 19, 2015
Filed:

Oct 27, 2014
Appl. No.:

14/524204
Inventors:

- South San Francisco CA, US
Robert Andrew Heald - Harlow, GB
Timothy Heffron - Burlingame CA, US
Graham Elgin Jones - Harlow, GB
Sussie Lerche Krintel - Harlow, GB
Neville James McLean - Harlow, GB
Chudi Ndubaku - San Francisco CA, US
Alan G. Olivero - Half Moon Bay CA, US
Laurent Salphati - San Francisco CA, US
Lan Wang - Foster City CA, US
Assignee:

Genentech, Inc. - South San Francisco CA
International Classification:

C07D 498/14
A61K 31/5377
A61K 31/5386
A61K 31/5383
C07D 498/20
C07D 491/147
A61K 39/395
US Classification:

4241331, 544115, 5142328, 544 73, 5142302, 544 71, 544 74
Abstract:

Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions.Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.